TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available.
Imagion Biosystems has completed the manufacturing of its MagSense® HER2 Breast Cancer Imaging Agent, marking a significant milestone in its Phase 2 clinical trial program. The company is collaborating with Siemens and Wayne State University to optimize imaging protocols, aiming to improve particle visualization and develop AI techniques. The recent AU$3.5 million capital raise will support the HER2 Phase 2 clinical trial and other cancer programs, with no expected impact from the U.S. federal government shutdown on the IND application timeline.
More about Imagion Biosystems Ltd.
Imagion Biosystems is a company focused on enhancing healthcare outcomes through early cancer detection using its proprietary MagSense® imaging technology. The company is developing a non-radioactive, precision diagnostic molecular imaging technology that combines biotechnology and nanotechnology to detect cancer and other diseases with higher specificity.
Average Trading Volume: 11,243,407
Technical Sentiment Signal: Buy
Current Market Cap: A$15.77M
See more data about IBX stock on TipRanks’ Stock Analysis page.